Skip to content
TrialMatch
Sign up
Recruiting

The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study).

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The i4i PRODICT® study has been developed to investigate the uptake and acceptability of the i4i PRODICT® test which combines both common and rare genetic changes (genetic variants) into one saliva-based DNA test to estimate a person's future risk of prostate cancer (PrCa) in people of varying ethnicities.

Condition
Prostate Cancer
Tested
The i4i PRODICT® test., Prostate cancer screening, MRI Scan, Prostate Biopsy
Sponsor
Institute of Cancer Research, United Kingdom

Who can join

Age
40 to 55 years
Sex
Male only
Healthy volunteers
Accepted

Inclusion 8

  • Minimum age: 40 years
  • Maximum age: 55 years
  • Eligible sex: Male
  • Study condition: Prostate Cancer
  • People with a prostate\* (PwP). \*People with a prostate is defined as people born male.
  • Aged 40 to 55 years.
  • People of either (i) Black African/Black African-Caribbean; (ii) White European; or (iii) South Asian or East Asian ancestry. These are defined as individuals with 4 grandparents of the same ancestry.
  • Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow-up schedule.

Exclusion 5

  • Previous diagnosis of prostate cancer.
  • People of mixed ancestry
  • Previous diagnosis of cancer with a life-expectancy of less than five years.
  • Negative prostate biopsy within one year before recruitment.
  • Any significant psychological conditions that may be worsened or exacerbated by participation in the study.

Where

3 sites, 3 recruiting

The Royal Marsden Hospital

London, United Kingdom

Recruiting

The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

Sutton, Surrey, United Kingdom

Recruiting

The Royal Marsden Hospital

Sutton, United Kingdom

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.